Oxipit ChestEye

🟢Active

ChestEye is Oxipit’s AI software suite for chest X-ray interpretation. Its applications can generate preliminary reports, identify radiographic findings, and automate reporting for selected normal studies.

Why Abandoned

Oxipit continues to list ChestEye on its official website, including current product and regulatory information. Public materials indicate commercial deployment; no shutdown or acquisition has been announced.

🩺 Health Signals

No checks have been run on this tool yet.

📅 Timeline

2018-03-22

Oxipit introduced ChestEye

2019-05-29

ChestEye received CE marking

2022-03-30

Oxipit raised €4.9 million

2022-04-05

Autonomous reporting deployed in Finland

🔄 Alternatives to Oxipit ChestEye

🪦 Other dead Healthcare tools

Frequently Asked Questions

What is Oxipit ChestEye?

Oxipit ChestEye is an AI suite for chest X-ray analysis. It supports radiologists by detecting findings, preparing report drafts, and, through related ChestEye applications, automating selected reporting workflows.

How does Oxipit ChestEye analyze chest X-rays?

ChestEye applies machine-learning models to digital chest radiographs, flags supported abnormalities, and converts results into structured or preliminary reporting output for clinician review, depending on the configured application and workflow.

Can Oxipit ChestEye replace a radiologist?

ChestEye is primarily positioned as radiology workflow and decision-support software. Oxipit’s ChestLink application is designed to autonomously finalize reports only for selected chest X-rays classified as having no abnormality, subject to local authorization and deployment controls.

Is Oxipit ChestEye CE marked?

Yes. Oxipit announced CE marking for ChestEye in 2019. Its website also presents regulatory information for individual applications; eligibility and permitted use should be checked for the specific product version and country.

Is Oxipit ChestEye available in the United States?

Availability depends on the specific ChestEye module and regulatory clearance. Healthcare organizations should confirm current FDA status and intended use directly with Oxipit before procurement or clinical deployment.